Patricia Barragan1, Daniel Podzamczer. 1. Hospital Universitari de Bellvitge, Feixa Llarga s/n L'Hospitalet de Llobregat, 08907, Barcelona, Spain. pbarragan@csub.scs.es
Abstract
BACKGROUND: Lopinavir is a protease inhibitor with high specificity for HIV-1 protease formulated with ritonavir. Numerous clinical trials have shown that lopinavir/ritonavir (LPV/r) is highly effective as a component of highly active antiretroviral therapy (HAART) regimens for HIV-1 infection. OBJECTIVE: In this article we provide an overview of the properties of LPV/r and the experience with its use in HIV-infected adults and adolescents. METHODS: We reviewed the literature and selected the most important published articles on LPV/r and the latest posters/communications presented in conferences, with particular attention to the clinical efficacy and tolerability of LPV/r in HIV-1 infected patients. CONCLUSION: LPV/r is highly effective as a component of HAART regimens for HIV-1 infection. There is considerable experience with the drug in both treatment-naive and treatment-experienced patients. In general, LPV/r is well tolerated and its high genetic barrier to resistance favours long-term efficacy.
BACKGROUND:Lopinavir is a protease inhibitor with high specificity for HIV-1 protease formulated with ritonavir. Numerous clinical trials have shown that lopinavir/ritonavir (LPV/r) is highly effective as a component of highly active antiretroviral therapy (HAART) regimens for HIV-1 infection. OBJECTIVE: In this article we provide an overview of the properties of LPV/r and the experience with its use in HIV-infected adults and adolescents. METHODS: We reviewed the literature and selected the most important published articles on LPV/r and the latest posters/communications presented in conferences, with particular attention to the clinical efficacy and tolerability of LPV/r in HIV-1 infectedpatients. CONCLUSION: LPV/r is highly effective as a component of HAART regimens for HIV-1 infection. There is considerable experience with the drug in both treatment-naive and treatment-experienced patients. In general, LPV/r is well tolerated and its high genetic barrier to resistance favours long-term efficacy.
Authors: Carlos K H Wong; Marshall C H Low; Ashley C Y Kwok; Angel Y C Lui; Kristy T K Lau; Ivan C H Au; Xi Xiong; Matthew S H Chung; Mike Y W Kwan; Eric H Y Lau; Benjamin J Cowling Journal: Paediatr Drugs Date: 2022-04-16 Impact factor: 3.930